Cyndeo Wealth Partners LLC Acquires 1,045 Shares of Eli Lilly and Company (NYSE:LLY)

Cyndeo Wealth Partners LLC grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 8.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,937 shares of the company's stock after acquiring an additional 1,045 shares during the period. Cyndeo Wealth Partners LLC's holdings in Eli Lilly and Company were worth $10,685,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $43,000. FPC Investment Advisory Inc. increased its holdings in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth $48,000. Capital A Wealth Management LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth $63,000. Finally, Bellwether Advisors LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $66,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $11.74 during trading hours on Monday, reaching $807.62. 2,819,360 shares of the company were exchanged, compared to its average volume of 3,654,950. The business has a 50 day moving average of $775.43 and a 200 day moving average of $801.69. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market capitalization of $765.41 billion, a P/E ratio of 68.97, a P/E/G ratio of 1.40 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period last year, the company posted $2.58 earnings per share. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's payout ratio is presently 48.82%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their target price for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. UBS Group dropped their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, June 7th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.